Trials Sponsors Conditions Drugs Pricing

Conditions

Cognition Disorders Multiple Sclerosis

Keywords

multiple sclerosiscognitive impairmentcognitive dysfunctionCognitive Dysfunction associated with Multiple Sclerosis

Outcome Measures

Primary Outcomes (2)

Symbol Digit Modalities Test, Oral Version (SDMT) - Total # Correct
Change from baseline
Subject's Global Assessment of Cognitive Change
Change from baseline

Interventions

C105Drug

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 65 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Males/females at least 18 years old and \< 65 years old, capable of understanding and complying with the protocol, including speaking and writing fluent English and having at least a 9th grade education
Clinically definite diagnosis per McDonald criteria of Multiple Sclerosis as confirmed by the Investigator (Relapsing-Remitting or Secondary Progressive)

Sponsors & Collaborators

Cognition Pharmaceuticals, LLC
Industrylead

Study Sites (30)

Saint Joseph's Hospital, Barrow Neurology Clinics

Phoenix, Arizona, 85013, United States

Northwest Neuro Specialists, PLLC

Tuscon, Arizona, 85741, United States

Research Center for Clinical Studies West

Lancaster, California, 93534, United States

Loma Linda University, Department of Neurology

Loma Linda, California, 92354, United States

Associated Neurologists, P.C.

Danbury, Connecticut, 06810, United States

Associated Neurologist of Southern Connecticut, PC

Fairfield, Connecticut, 06824, United States

Yale University MS Center

MeSH Terms

Conditions

Cognition DisordersMultiple SclerosisCognitive Dysfunction

Condition Hierarchy (Ancestors)

Neurocognitive DisordersMental DisordersDemyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

Frederick Munschauer, MD
SUNY Buffalo
PRINCIPAL INVESTIGATOR
Ralph Benedict, PhD
SUNY Buffalo
PRINCIPAL INVESTIGATOR

Study Design

Study Type: interventional
Phase: phase 2
Allocation: RANDOMIZED
Masking: QUADRUPLE
Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

September 12, 2007

First Posted

September 14, 2007

Study Start

November 2006

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

March 2008

Actual (reported)

A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (30)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (30)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations